---
schema_version: "secwatch.filing_event.v1"
accession: "0001365916-23-000034"
form_type: "8-K"
ticker: null
cik: "0001365916"
company_name: "AMYRIS, INC."
filed_at: "2023-04-04T23:59:59+00:00"
generated_at: "2026-06-17T06:24:49.821773+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amyris closes $200M asset sale to Givaudan, buys remaining 49% of Aprinnova for $49M

## Summary
- Sold cosmetic ingredients assets to Givaudan for $200M upfront cash plus up to $150M performance earnout over three years.
- Total estimated value including near- and long-term manufacturing partnership is approximately $500M.
- Purchased 49% of Aprinnova from Nikko Chemicals and Nissa for $49M cash, increasing Amyris ownership to 99%.
- Both transactions closed on April 3, 2023, as previously announced.
- Long-term partnership with Givaudan for Amyris to manufacture cosmetic ingredients.

## SEC filing metadata
- accession: 0001365916-23-000034
- form_type: 8-K
- cik: 0001365916
- company_name: AMYRIS, INC.
- filed_at: 2023-04-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1365916/000136591623000034/0001365916-23-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1365916/000136591623000034/amrs-20230403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001365916-23-000034
- JSON: https://secwatch.observer/filing/0001365916-23-000034.json
- Plain text: https://secwatch.observer/filing/0001365916-23-000034.txt

## Key facts
- M&A Transactions
  AMYRIS, INC. completed a disposition involving Givaudan SA for $200 million upfront cash consideration and up to $150 million in performance-based earnout payments over three years (closed 2023-04-03).
  - Action: disposition
  - Counterparty: Givaudan SA
  - Consideration: $200 million upfront cash consideration and up to $150 million in performance-based earnout payments over three years
  - Closing: 2023-04-03
  source text: to distribute, market and sell Neossance® Squalane emollient, Neossance® Hemisqualane silicone alternative and CleanScreenTM sun protector in cosmetics actives, to Givaudan for $200 million upfront cash consideration and up to $150 million in performance-based earnout payments over three years. In addition, the parties entered into a long-term partnership agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1365916/000136591623000034/0001365916-23-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.